S1-221

N/A

Report date: 2025/09/02 20:00:09

Base Information

Drug NameS1-221
Drug Alias Namecannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC)S1-221
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCannabinoid CB2 receptor inverse agonistsCannabinoid CB1 receptor inverse agonistsSerotonin 5-HT1 receptors modulators +[5] 
TargetsCannabinoid CB1 receptorCannabinoid CB2 receptorSerotonin 5-HT1 receptors +[5] 
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsYes
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDelphian Therapeutics Australia Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDelphian Therapeutics Australia Pty Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A